NPY and granular corneal dystrophy type II: In this study, the administration of the CB1 receptor antagonist was able to ameliorate the behavioral signs that followed withdrawal from chronic ACD; this effect was accompanied by a time- and region-dependent increase in the number of NPY-positive neurons both in the hippocampus and in the NAc.